We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CD44 Promotes Lung Cancer Cell Metastasis through ERK–ZEB1 Signaling.
- Authors
Wang, Yen-Yun; Vadhan, Anupama; Chen, Ping-Ho; Lee, Yen-Lung; Chao, Chih-Yeh; Cheng, Kuang-Hung; Chang, Yu-Chiuan; Hu, Stephen Chu-Sung; Yuan, Shyng-Shiou F.
- Abstract
Simple Summary: Lung cancer treatment has always been challenging as its metastasis rate is higher than other cancers. Cancer stemness promotes cancer metastasis, and it is important to understand the mechanism behind the cancer-stemness-mediated metastasis. CD44 is a well-known cancer stem cell marker and plays a role in tumor metastasis in different cancer types. In this study, we investigated the role of CD44 in lung cancer metastasis by using clinical studies as well as in vitro and in vivo studies. We found that CD44 promotes the migration and invasion abilities of lung cancer cells through ERK–ZEB1 signaling. This study provided evidence that CD44 may be a possible therapeutic target to decrease lung cancer metastasis. Lung cancer is a malignancy with high mortality worldwide, and metastasis occurs at a high frequency even when cancer spread is not detectable at primary operation. Cancer stemness plays an important role in malignant cancer behavior, treatment resistance, and cancer metastasis. Therefore, understanding the molecular pathogenesis behind cancer-stemness-mediated metastasis and developing effective approaches to prevent metastasis are key issues for improving cancer treatment. In this study, we investigated the role of CD44 stemness marker in lung cancer using in vitro and clinical studies. Immunohistochemical staining of lung cancer tissue specimens revealed that primary tumors with higher CD44 expression showed increased metastasis to regional lymph nodes. Flow cytometry analysis suggested that CD44 positive cells were enriched in the metastatic lymph nodes compared to the primary tumors. CD44 overexpression significantly increased migration and invasion abilities of lung cancer cells through CD44-induced ERK phosphorylation, ZEB1 upregulation, and Claudin-1 downregulation. Furthermore, ERK inhibition suppressed the migration and invasion abilities of CD44-overexpressing lung cancer cells. In summary, our in vitro and clinical results indicate that CD44 may be a potential prognostic and therapeutic marker for lung cancer patients.
- Subjects
IN vitro studies; FLOW cytometry; IN vivo studies; STAINS &; staining (Microscopy); CANCER invasiveness; IMMUNOHISTOCHEMISTRY; LUNG tumors; METASTASIS; METABOLISM; CELLULAR signal transduction; CANCER patients; CELL motility; MOLECULAR biology; DNA-binding proteins; T cells; MITOGEN-activated protein kinases; PHOSPHORYLATION
- Publication
Cancers, 2021, Vol 13, Issue 16, p4057
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13164057